Related Experiment Video
Updated: Apr 21, 2026
06:07
Continuous Fluorescence-Based Endonuclease-Coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors
Published on: August 5, 2022
2.5K
Identifying novel selective non-nucleoside DNA methyltransferase 1 inhibitors through docking-based virtual screening
Shijie Chen1, Yulan Wang, Wen Zhou
1State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203, China.
Journal of Medicinal Chemistry
|October 22, 2014
Summary
Researchers identified novel non-nucleoside inhibitors targeting DNA methyltransferase 1 (DNMT1) for cancer therapy. These compounds show potency and selectivity, inhibiting cancer cell proliferation effectively.
Area of Science:
- Biochemistry
- Molecular Biology
- Cancer Research
Background:
- DNA methyltransferases (DNMTs) are crucial for maintaining DNA methylation patterns and are key targets in cancer chemotherapy.
- Existing DNMT inhibitors, primarily nucleoside analogs, often exhibit toxicity and lack specificity.
Purpose of the Study:
- To identify novel, non-nucleoside inhibitors of DNMT1 with improved potency and selectivity.
- To analyze the structure-activity relationships (SAR) and binding modes of these inhibitors for future drug development.
Main Methods:
- Docking-based virtual screening was employed to identify initial lead compounds.
- Biochemical analyses were used to determine IC50 values and selectivity.
- Similarity-based analog searching was performed to enhance compound potency.
Main Results:
- A novel non-nucleoside DNMT1 inhibitor, DC_05, was identified with low micromolar IC50 values and selectivity.
- Analog compounds, DC_501 and DC_517, demonstrated greater potency than DC_05.
- All three identified compounds significantly inhibited cancer cell proliferation.
Conclusions:
- Novel non-nucleoside DNMT1 inhibitors offer a promising alternative to existing therapies.
- The identified compounds and their SAR provide a foundation for developing more effective and specific cancer therapeutics targeting DNMT1.
